Fármacos antiepilépticos utilizados en la infancia. Nuevos productos y nuevos conceptos

Axpe, C. Garaizar; Bello, Anne-Claire; Concha, T. Pérez; Isasi, M. Â Herrera; Larrinaga, A. Álvarez Ruiz de

doi:10.1016/s1695-4033(03)78017-5

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La fenitoína, que tiene las tres características mencionadas, y la carbamacepina, que tiene las dos primeras, son más suscep tibles que otros como el valproato. Si asumimos este modelo, tenemos que decir que los nuevos antiepilépticos no se ajustan a este perfil de riesgo, ya que presentan una cinética lineal, tienen en general un amplio rango terapéutico y una muy buena absor ción oral [7,34,35].…”

Section: Especialidades Farmacéuticas Genéricas En El Tratamiento De unclassified

Fármacos genéricos en el tratamiento de la epilepsia

Dios

Ochoa-Sangrador²,

Sempere³

2005

RevNeurol

View full text Add to dashboard Cite

We discuss some controversial aspects with prescription of generic drugs (GD) and the problems concerning bioequivalence, mainly in the case of drugs with non-linear pharmacokinetics and/or narrow therapeutic rank, like the anti epileptic drugs (AED). Development. There is considerable debate about GD in the treatment of epilepsy, with clearly advantages (cost saving) and disadvantages (loos of seizure control or drug toxicity) in prescribing generics anticonvulsivants. We make a systematic review of the literature in primary (PubMed) and secondary (Tripdatabase and Cochrane Library) bibliographic databases in relation to GD and AED. The main information is about classical AED (phenytoin, carbamazepine, valproic acid and primidone) and we don't found studies in this area about the new AED. The level of evidence is, generally, weak, based on case-series and expert opinion without explicit critical appraisal (except in phenytoin with level of evidence moderate, based on some analytical studies). In Spain, at this moment, there are only two generic AED, one-classical (carbamazepine) and one-new (gabapentin). Conclusion. The American Academy of Neurology and Epilepsy Foundation maintains that the individual and physician should be notified and give their consent before a switch in antiepileptic medications is made, whether it involves generic substitution for brand name products, or generic to generic substitutions.

show abstract

Section: Especialidades Farmacéuticas Genéricas En El Tratamiento De unclassified